Restructuring and Related Charges

3 Months Ended

Dec. 27, 2013

Restructuring and Related Activities [Abstract]

Restructuring and Related Charges

5. Restructuring and Related Charges

During fiscal 2013, the Company launched a restructuring program designed to improve its cost structure ("the 2013 Mallinckrodt Program"). The 2013 Mallinckrodt Program includes actions across both segments, as well as within corporate functions. The Company expects to incur charges of $100.0 million to $125.0 million under this program as the specific actions required to execute on these initiatives are identified and approved, most of which are expected to be incurred by the end of fiscal 2016.

Prior to Separation, Covidien initiated restructuring programs, which also applied to its Pharmaceutical business. Restructuring actions associated with acquisitions made prior to the Separation are included within Other programs below. These programs were substantially completed as of September 27, 2013.

Net restructuring and related charges by segment were as follows:

	Three Months Ended
	December 27, 2013			December 28, 2012
Specialty Pharmaceuticals	$	—		$	0.7
Global Medical Imaging	8.1			0.3
Restructuring and related charges, net	8.1			1.0
Less: accelerated depreciation	(0.1		)	(0.8		)
Restructuring charges, net	$	8.0		$	0.2

Net restructuring and related charges were comprised of the following:

	Three Months Ended
	December 27, 2013			December 28, 2012
2013 Mallinckrodt Program	$	8.3		$	—
Other programs	(0.2		)	1.0
Total programs	8.1			1.0
Less: non-cash charges, including accelerated depreciation	(0.1		)	(0.9		)
Total charges expected to be settled in cash	$	8.0		$	0.1

The following table summarizes cash activity for restructuring reserves, substantially all of which related to employee severance and benefits:

	2013 Mallinckrodt Program			Other Programs			Total
Balance at September 27, 2013	$	14.9		$	10.6		$	25.5
Charges	10.2			0.3			10.5
Changes in estimate	(2.0		)	(0.5		)	(2.5		)
Cash payments	(2.2		)	(3.7		)	(5.9		)
Balance at December 27, 2013	$	20.9		$	6.7		$	27.6

Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2013 Mallinckrodt Program were as follows:

Specialty Pharmaceuticals	$	2.4
Global Medical Imaging	17.6
Corporate	3.0
	$	23.0

Substantially all of the restructuring reserves were included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets.